Navigation Links
Appeals Court Rules in Favor of Prometheus, Upholds the Patentability of Its Claims for Methods of Thiopurine Metabolite Testing
Date:9/17/2009

SAN DIEGO, Sept. 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in favor of Prometheus in a dispute over the validity of its patents that cover the methods for a diagnostic test that enables physicians to optimize ongoing dosing of thiopurines to reach and maintain desired therapeutic levels (U.S. Patent Nos. 6,355,623 and 6,680,302).

The patents were challenged by Mayo Clinic and Mayo's medical laboratory division on several grounds. The Federal Court ruling not only reversed the judgment of the district court, but also remanded the case to the district court with express instructions to deny Mayo's motion for summary judgment, which alleged that the patents' claims did not describe patentable subject matter.

"This clear-cut ruling by the U.S. Court of Appeals for the Federal Circuit did not simply remand but completely reversed the judgment of the U.S. District Court," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "Prometheus is committed to developing and commercializing innovative diagnostics and other products to help physicians improve patient lives. As a key element in enabling this strategy, we have historically taken the strong position that we will vigorously defend any intellectual property rights that we own or license, and we will continue to do the same going forward."

PROMETHEUS(R) Thiopurine Metabolites helps keep patients' drug metabolite levels within an optimal therapeutic range, thereby increasing the probability of a positive response and potentially reducing the need for other medications. Thiopurine metabolites testing helps identify some of the reasons for treatment failure and monitor for potential toxicity before it occurs.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and intends to apply these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Appeals Court Affirms Patent Infringement Rulings Against Roches peg-EPO Product
2. Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces
3. The American Legion Appeals to Congress for Compassionate Treatment of Women Veterans
4. Providence Service Corporation Comments on U.S. Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10% Cut in Medi-Cal Payments
5. Federal Appeals Court Protects California Home Care Pay
6. Cosmetic surgery appeals to men, women with appearance-based rejection sensitivity
7. Appeals Court OKs Multimillion-Dollar Judgment for Dallas Doctor
8. Congress Appeals to Obama Administration, Thailand: Stop Hmong Returns to Laos
9. UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan
10. LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception
11. U.S. Court of Appeals Affirms 2006 Lower Court Ruling That Tobacco Companies Committed Fraud for Five Decades and Lied About the Dangers of Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop action ... author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He now ... teaching English. He is heavily involved in the youth group of his local church. ...
(Date:4/24/2017)... ... , ... A 2-in-1 bottleless water appliance provides both purified ... Texas, here are the ways in which this technology can benefit dental offices: ... fresh, oxygenated water, with both cold and hot options. , Convenience for Dentists ...
(Date:4/22/2017)... NY (PRWEB) , ... April 22, 2017 , ... ... which shows that U.S. consumers can save an average of 70% when buying ... savings (up to 97%) are available when purchasing from other countries. The report ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: